XOMA Corporation (XOMA), a biotech royalty aggregator, said on Tuesday that its Board has authorized first share repurchase program to buy back up to $50 million of shares through January 2027.
"Balanced capital allocation strategy looks to return capital to shareholders while continuing to invest in royalty and milestone acquisitions," XOMA said in a statement.
XOMA was trading down by 1.08 percent at $18.30 per share in the pre-market trade on the Nasdaq.
For comments and feedback: editorial@rttnews.com